Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RAND Report Author’s Comments Show Bias, Ephedra Education Council Says

This article was originally published in The Tan Sheet

Executive Summary

Recent comments by Paul Shekelle, MD/PhD and RAND Corp. colleagues represent "a dramatic departure from the objective, peer-reviewed findings of the RAND report" on ephedra, according to Ephedra Education Council General Counsel Wes Siegner

You may also be interested in...



RAND Report Recommends Case-Control Ephedra Study Look At AE Risk

A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS095535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel